Molbio Diagnostics Ltd
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-
of-care (POC) molecular diagnostics
company engaged in the research,
development, manufacturing, and commercialization of rapid diagnostic
solutions.[1]
- Market Cap ₹ 10,039 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 60.2
- Book Value ₹
- Dividend Yield %
- ROCE 23.8 %
- ROE 17.2 %
- Face Value ₹ 1.00
Pros
- Debtor days have improved from 117 to 68.6 days.
- Company's working capital requirements have reduced from 140 days to 90.7 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 837 | 1,020 | 1,446 | |
| 602 | 760 | 1,126 | |
| Operating Profit | 234 | 260 | 319 |
| OPM % | 28% | 26% | 22% |
| -49 | -4 | 9 | |
| Interest | 14 | 18 | 33 |
| Depreciation | 41 | 45 | 64 |
| Profit before tax | 130 | 194 | 231 |
| Tax % | 36% | 29% | 29% |
| 84 | 139 | 164 | |
| EPS in Rs | 452.37 | 64.34 | 14.77 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 17% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 2 | 2 | |
| Reserves | 821 | 966 | |
| 184 | 147 | ||
| 211 | 346 | ||
| Total Liabilities | 1,218 | 1,461 | |
| 289 | 290 | ||
| CWIP | 2 | 27 | |
| Investments | 6 | 46 | |
| 921 | 1,099 | ||
| Total Assets | 1,218 | 1,461 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 10 | 287 | 50 | |
| -45 | -123 | -93 | |
| -32 | -26 | 276 | |
| Net Cash Flow | -67 | 138 | 233 |
| Free Cash Flow | -7 | 232 | 1 |
| CFO/OP | 23% | 141% | 38% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 186 | 97 | |
| Inventory Days | 338 | 384 | |
| Days Payable | 101 | 203 | |
| Cash Conversion Cycle | 423 | 278 | |
| Working Capital Days | 200 | 128 | |
| ROCE % | 21% |
Documents
Annual reports
No data available.